Kancera: Positive top-line results in KANDOVA study - Redeye

Redeye comments on Kancera reporting positive top-line results in its phase Ib/IIa KANDOVA study with KAND567 in ovarian cancer. Although the study was small and not placebo-controlled, we are encouraged by the signals. Earlier, we lowered our expectations for the study, but now we make upward adjustments to the program, leading to an increased valuation range.

Länk till analysen i sin helhet: https://www.redeye.se/research/1115472/kancera-positive-top-line-results-in-kandova-study?utm_source=finwire&utm_medium=RSS